Waters Accelerates Oligonucleotide Bioanalysis with the Launch of OligoWorks SPE Workflow and Kits

News Summary:

• Delivers up to 2x^[i] higher oligonucleotide recovery from biofluids with improved LC-MS sensitivity and reproducibility to support robust quantitation.
• Faster time-to-results for expanded range of bioanalysis projects enabled through enhanced LC-MS sensitivity, and standardized protocols that reduce method development and sample processing time.
• Simplifies laborious sample preparation workflows, improves robustness and repeatability, addresses poor/inconsistent recoveries, while enabling greater MS sensitivity, accuracy, and precision.

MILFORD, Mass., Oct. 19, 2023 /PRNewswire/ -- Waters Corporation (WAT:NYSE) announces the launch of OligoWorks SPE (solid phase extraction) Kits and components to improve sample preparation for LC-MS-based bioanalytical quantitation of therapeutic oligonucleotides. Pharma and biopharma companies developing oligonucleotide therapeutics and the Contract Research Organizations (CROs) that support them can now realize up to a 2x^[i] increase over competing products in oligonucleotide recovery from biofluids. The Kits deliver greater reproducibility and LC-MS sensitivity, enabling lower limits of quantitation and reducing the need for repeat experiments.

The pipeline for oligonucleotide therapeutics is rapidly expanding with thirteen FDA approved oligonucleotide therapeutics today, and 500+ in the pipeline. While potent, these highly modified oligonucleotides are challenging to precisely quantify during dosing, metabolism, and tissue distribution studies.

"As a leader in supporting drug development, Waters is committed to solving customer pain points, and enabling greater analytical performance and productivity. Our new OligoWorks SPE Kits directly address oligonucleotide bioanalysis sample prep challenges across diverse oligo therapeutics," said Erin Chambers, Vice President, Consumables and Lab Automation, Waters Corporation. "The science and societal effects of these therapies are exploding given their ability to address human health issues. Our workflow and kits will drive an acceleration of oligo bioanalysis projects and drug development timelines; ultimately improving the experience for drug candidates."